2016
Cardiovascular Disease Risk Factors in Ghana during the Rural-to-Urban Transition: A Cross-Sectional Study
Kodaman N, Aldrich MC, Sobota R, Asselbergs FW, Poku KA, Brown NJ, Moore JH, Williams SM. Cardiovascular Disease Risk Factors in Ghana during the Rural-to-Urban Transition: A Cross-Sectional Study. PLOS ONE 2016, 11: e0162753. PMID: 27732601, PMCID: PMC5061429, DOI: 10.1371/journal.pone.0162753.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overBlood GlucoseBlood PressureBody Mass IndexCardiovascular DiseasesCholesterolCholesterol, HDLCholesterol, LDLCross-Sectional StudiesDiabetes Mellitus, Type 2FemaleGhanaHumansHypertensionMaleMiddle AgedObesityPlasminogen Activator Inhibitor 1PrevalenceRisk FactorsSmokingSurveys and QuestionnairesTissue Plasminogen ActivatorTriglyceridesUrbanizationYoung AdultConceptsCardiovascular disease risk factorsDisease risk factorsRisk factorsUrban residenceWorse cardiovascular risk profileCardiovascular risk profileRelated clinical outcomesPopulation-based surveyCross-sectional studyFibrinolytic markersTotal cholesterolCholesterol profileClinical outcomesLDL cholesterolCardiovascular diseaseBMI adjustmentHigh riskRural participantsRisk profileLarger studyT-PAUrban womenUrban menObesityCholesterol
2015
Phenotype-Driven Plasma Biobanking Strategies and Methods
Bowton EA, Collier SP, Wang X, Sutcliffe CB, Van Driest SL, Couch LJ, Herrera M, Jerome RN, Slebos RJ, Alborn WE, Liebler DC, McNaughton CD, Mernaugh RL, Wells QS, Brown NJ, Roden DM, Pulley JM. Phenotype-Driven Plasma Biobanking Strategies and Methods. Journal Of Personalized Medicine 2015, 5: 140-152. PMID: 26110578, PMCID: PMC4493492, DOI: 10.3390/jpm5020140.Peer-Reviewed Original ResearchDNA biorepositoryElectronic medical record databaseMedical record databaseRoutine clinical testingGenotype-phenotype interactionsClinical outcomesGenomic researchClinical dataClinical careClinical testingRecord databaseClinical researchMetabolomics approachBiobank developmentPersonalized medicineBioVUSample collectionGenomics
2008
Association of a CYP4A11 Variant and Blood Pressure in Black Men
Gainer JV, Lipkowitz MS, Yu C, Waterman MR, Dawson EP, Capdevila JH, Brown NJ, Group A. Association of a CYP4A11 Variant and Blood Pressure in Black Men. Journal Of The American Society Of Nephrology 2008, 19: 1606-1612. PMID: 18385420, PMCID: PMC2488260, DOI: 10.1681/asn.2008010063.Peer-Reviewed Original ResearchConceptsHypertensive renal diseaseRenal diseaseClinical outcomesHigher systolic BPAdverse clinical outcomesWhite individualsRegulation of BPEndogenous arachidonic acidBlack menBaseline proteinuriaCYP4A11 variantsHypertensive nephrosclerosisRenal vasoconstrictorClinical characteristicsCumulative incidenceRenal functionBlood pressureDiastolic BPHigher systolicSystolic BPHigh BPKidney diseasePulse pressureMale miceHypertension
2002
Comparative Effects of Estrogen and Angiotensin-Converting Enzyme Inhibition on Plasminogen Activator Inhibitor-1 in Healthy Postmenopausal Women
Brown NJ, Abbas A, Byrne D, Schoenhard JA, Vaughan DE. Comparative Effects of Estrogen and Angiotensin-Converting Enzyme Inhibition on Plasminogen Activator Inhibitor-1 in Healthy Postmenopausal Women. Circulation 2002, 105: 304-309. PMID: 11804984, DOI: 10.1161/hc0302.102570.Peer-Reviewed Original ResearchMeSH KeywordsAldosteroneAngiotensin IIAngiotensin-Converting Enzyme InhibitorsBlood PressureCardiovascular DiseasesCross-Over StudiesDrug Therapy, CombinationEstradiolEstrogen Replacement TherapyEstrogens, Conjugated (USP)FemaleHumansMiddle AgedPlasminogen Activator Inhibitor 1Polymorphism, GeneticPostmenopauseRamiprilReninSingle-Blind MethodTissue Plasminogen ActivatorConceptsHealthy postmenopausal womenPAI-1 4G/5G genotypePlasma renin activityPostmenopausal womenPAI-1 concentrationsACE inhibitionTissue plasminogen activatorConjugated estrogensPAI-1G genotypeRenin activityAngiotensin IIPlasminogen activator inhibitor-1 (PAI-1) concentrationsAngiotensin-Converting Enzyme InhibitionPAI-1 antigen concentrationsPlasminogen activatorConjugated equine estrogensEffects of estrogenPlasminogen activator inhibitor-1Activator inhibitor-1Combination estrogenClinical outcomesEquine estrogensCombined therapyCrossover treatment